Neurowyzr provides digital brain health measurement tools that utilize advanced analytics and AI for the early detection and monitoring of cognitive decline. By offering objective and accessible assessments, the platform helps individuals identify potential brain health issues before they lead to serious conditions like dementia or Alzheimer's disease.
Funding
$5.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JVFounders
Product
Problem
Cognitive decline can begin as early as age 30, often progressing silently and undetected. Traditional methods for assessing brain health are not always accessible or affordable, hindering early detection and timely intervention for conditions like dementia and Alzheimer's disease.
Solution
Neurowyzr offers digital brain health measurement tools that leverage advanced analytics and artificial intelligence to facilitate early detection and monitoring of cognitive decline. The platform provides objective and accessible assessments of brain function, enabling individuals and healthcare providers to identify potential issues before they escalate. By detecting early signs of decline, Neurowyzr aims to improve the management of brain health and enhance overall quality of life. The solution is designed to be affordable and scalable, making brain health screening more accessible to a wider population.
Target Audience
The primary target audience includes healthcare providers, pharmaceutical companies, and individuals aged 40 and above who are concerned about early brain decline.
Features
- Digital brain function screening for objective and accessible assessment.
- AI-powered analytics for early detection of cognitive decline.
- Monitoring capabilities to track changes in brain health over time.
- Scalable platform suitable for healthcare providers and pharmaceutical companies.
- ISO 27001:2013 certified for data privacy and information security.